Russia Develops Groundbreaking Drug to Prevent Blood Clots During Heart Attacks

Tackling Myocardial Infarction

Russian scientists have developed a highly promising new drug named "Angipor" to drastically improve heart attack treatments. The medication is specifically designed to prevent deadly blood clots from forming during myocardial infarctions. Viktor Sirotenko, Dean of the Faculty of Pharmacy at Volgograd State Medical University and one of the drug's lead developers, confirmed the breakthrough to the Russian news agency Sputnik. Angipor belongs to the class of antiplatelet agents and is currently undergoing its final stage of clinical trials.

Safer Stenting Procedures

Cardiologists heavily rely on antiplatelet drugs during stenting procedures to open blocked coronary arteries. However, traditional medications often carry severe risks of internal bleeding. Clinical trials show that Angipor is significantly superior to currently used comparator drugs on the market. Preliminary results indicate the new medication drastically reduces the dangerous risk of bleeding. This solves one of the most prominent and life-threatening complications associated with standard antiplatelet therapy.

Independent Production

Russia plans to manufacture the drug entirely within its own borders to ensure supply chain security. Sirotenko explained that the entire production cycle will take place inside the country. The manufacturing process will not rely on any foreign raw materials, equipment, or medical supplies. Developers expect to officially launch Angipor on the medical market within the next two years.

Track the latest global medical breakthroughs. Get your healthcare news directly on Oman Day.